Secondary Prevention of Ischemic Stroke in Urban China

被引:85
|
作者
Wei, Jade W. [1 ]
Wang, Ji-Guang [2 ]
Huang, Yining [3 ]
Liu, Ming [4 ]
Wu, Yangfeng [5 ]
Wong, Lawrence K. S. [6 ]
Cheng, Yan [7 ]
Xu, En [8 ]
Yang, Qidong [9 ]
Arima, Hisatomi [1 ]
Heeley, Emma L. [1 ]
Anderson, Craig S. [1 ]
机构
[1] Royal Prince Alfred Hosp, George Inst Int Hlth, Camperdown, NSW 2050, Australia
[2] Shanghai Jiao Tong Univ, Ctr Epidemiol Studies & Clin Trials, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
[3] Peking Univ, Hosp 1, Dept Neurol, Beijing 100871, Peoples R China
[4] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, George Inst China, Beijing 100871, Peoples R China
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[7] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
[8] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
[9] Ctr S Univ, Xiangya Hosp, Changsha, Peoples R China
关键词
China; prevention; stroke; 1ST-EVER STROKE; ATTACK; INTERVENTION; GUIDELINES; ADHERENCE; VALIDITY; HISTORY; CARE;
D O I
10.1161/STROKEAHA.109.571463
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We aimed to describe the uptake of proven secondary prevention strategies for ischemic stroke in urban China. Methods-In a prospective, multicenter, hospital-based registry of 4782 cases of acute ischemic stroke in China during 2006, the use of secondary prevention regimens was evaluated before hospital discharge and 3 and 12 months after stroke. Logistic regression analysis was performed to determine associations between various baseline variables and in-hospital use of antihypertensive, antiplatelet, and lipid-lowering therapies, and to identify variables associated with their continuation at 12 months. Results-In-hospital initiation of antihypertensive (63%), antiplatelet (81%), and lipid-lowering (31%) therapies was influenced favorably by previous use and comorbid cardiovascular risk factors and unfavorably by stroke severity. Antihypertensive use was well-maintained during follow-up, whereas use of antiplatelet and lipid-lowering therapy decreased (66% and 17%, respectively; P<0.001) by 12 months after stroke, with discontinuation related to patient and physician factors. Interpretation-There was a high level of uptake of secondary prevention for ischemic stroke in this nationwide sample of hospitalized patients in urban China. However, use of antiplatelet and lipid-lowering therapy declined substantially after discharge, apparently related to misperceptions of subsequent disease risk by both doctors and patients. (Stroke. 2010;41:967-974.)
引用
收藏
页码:967 / 974
页数:8
相关论文
共 50 条
  • [21] Current aspects of secondary prevention of ischemic stroke
    Weber, R.
    Diener, H. C.
    Grond, M.
    NERVENARZT, 2007, 78 (10): : 1138 - +
  • [22] Adherence to aspirin in secondary prevention of ischemic stroke
    Lago, Aida
    Tembl, Jose Ignacio
    Pareja, Ana
    Ponz, Alejandro
    Ferrer, Jose Manuel
    Valles, Juana
    Santos, Maria Teresa
    CEREBROVASCULAR DISEASES, 2006, 21 (5-6) : 353 - 356
  • [23] Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke
    Pace, Wilson D.
    Earl, Ali
    Bryant, Casey
    Hansen, Cory
    US PHARMACIST, 2020, 45 (01) : HS8 - HS12
  • [24] Secondary Prevention of Ischemic Stroke - Part 2
    Hamann, G. F.
    Liebetrau, M.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2013, 81 (01) : 44 - 53
  • [25] Statins and secondary prevention of ischemic and hemorrhagic stroke
    Squizzato, Alessandro
    Dentali, Francesco
    Romualdi, Erica
    Ageno, Walter
    STROKE, 2008, 39 (07) : E113 - E113
  • [26] Antiplatelet agents for secondary prevention of ischemic stroke
    Majid, A
    Delanty, N
    Kantor, J
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (10) : 1241 - 1247
  • [27] Secondary prevention of ischemic non cardioembolic stroke
    Armario, Pedro
    Pinto, Xavier
    Soler, Cristina
    Cardona, Pere
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2015, 27 (06): : 287 - 300
  • [28] Antiaggregation therapy is a secondary prevention of ischemic stroke
    Kamchatnov, P. R.
    Chugunov, A. V.
    Umarova, Kh. Ya.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2008, : 58 - 64
  • [29] Primary and secondary prevention of ischemic stroke in diabetes
    Geisler, F.
    Endres, M.
    Jungehuelsing, G. J.
    DIABETOLOGE, 2013, 9 (03): : 204 - 209
  • [30] Secondary prevention of ischemic stroke: aspirin or ticlopidine
    Zarranz, JJ
    MEDICINA CLINICA, 1998, 111 (13): : 518 - 518